Dr. Larkin on Lenvatinib Plus Everolimus in Patients With RCC

Video

James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus versus either agent alone in patients with renal cell carcinoma.

James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus, single-agent lenvatinib, and single-agent everolimus in patients with renal cell carcinoma (RCC).

The three-arm study looked at patients who previously received sunitinib or pazopanib, Larkin explains. In patients who received everolimus, PFS was approximately 5 months, while PFS was 7 months in patients who received lenvatinib. Patients who received the combination had a median PFS of 14 months.

Toxicities associated with the combination, which included high blood pressure and diarrhea, were manageable and expected.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD